Vasopeptidase inhibition

This publication has 20 references indexed in Scilit:

• Modulation of Functionally Active Endothelin-Converting Enzyme by Chronic Neutral Endopeptidase Inhibition in Experimental Atherosclerosis
  Circulation, 2000
• Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition
  Journal of the American College of Cardiology, 2000
• The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides
  British Journal of Clinical Pharmacology, 1997
• Suppression of Atherosclerotic Changes in Cholesterol-Fed Rabbits Treated With an Oral Inhibitor of Neutral Endopeptidase 24.11 (EC 3.4.24.11)
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1996
• Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
  Proceedings of the National Academy of Sciences, 1994
• Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II
  Journal Of Hypertension, 1993
• Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure.
  Circulation, 1992
• Role of neutral endopeptidase in the metabolism of endothelin.
  Hypertension, 1992
• Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
  Journal of Clinical Investigation, 1991
• Role of endopeptidase‐24.11 in the inactivation of atrial natriuretic peptide
  FEBS Letters, 1988